4/10
01:16 pm
ptgx
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $80.00 price target on the stock.
Low
Report
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $80.00 price target on the stock.
3/28
09:52 am
ptgx
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $70.00 price target on the stock.
Low
Report
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $70.00 price target on the stock.
3/15
04:48 pm
ptgx
Is Protagonist Therapeutics, Inc. (PTGX) the Best Healthcare Stock For Long-Term Investment? [Yahoo! Finance]
Low
Report
Is Protagonist Therapeutics, Inc. (PTGX) the Best Healthcare Stock For Long-Term Investment? [Yahoo! Finance]
3/12
01:52 pm
ptgx
Protagonist Therapeutics Soars as Icotrokinra Drives Breakthrough Success [Yahoo! Finance]
Low
Report
Protagonist Therapeutics Soars as Icotrokinra Drives Breakthrough Success [Yahoo! Finance]
3/12
01:52 pm
ptgx
J&J and Protagonist's icotrokinra scores in Phase IIb UC study [Yahoo! Finance]
Low
Report
J&J and Protagonist's icotrokinra scores in Phase IIb UC study [Yahoo! Finance]
3/12
10:04 am
ptgx
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) had its "outperform" rating re-affirmed by analysts at Wedbush.
Medium
Report
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) had its "outperform" rating re-affirmed by analysts at Wedbush.
3/11
12:53 pm
ptgx
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) had its price target raised by analysts at Truist Financial Co. from $60.00 to $76.00. They now have a "buy" rating on the stock.
Medium
Report
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) had its price target raised by analysts at Truist Financial Co. from $60.00 to $76.00. They now have a "buy" rating on the stock.
3/11
08:56 am
ptgx
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) had its price target raised by analysts at BMO Capital Markets from $62.00 to $72.00. They now have an "outperform" rating on the stock.
Medium
Report
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) had its price target raised by analysts at BMO Capital Markets from $62.00 to $72.00. They now have an "outperform" rating on the stock.
3/11
07:18 am
ptgx
Why Protagonist Therapeutics, Inc. (PTGX) Went Up on Monday [Yahoo! Finance]
Medium
Report
Why Protagonist Therapeutics, Inc. (PTGX) Went Up on Monday [Yahoo! Finance]
3/10
11:09 am
ptgx
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) was given a new $73.00 price target on by analysts at BTIG Research.
Low
Report
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) was given a new $73.00 price target on by analysts at BTIG Research.
3/10
10:33 am
ptgx
Protagonist Therapeutics Unveils 'Paradigm-Shifting' Drug And Breaks Out [Yahoo! Finance]
Medium
Report
Protagonist Therapeutics Unveils 'Paradigm-Shifting' Drug And Breaks Out [Yahoo! Finance]
3/10
08:37 am
ptgx
Protagonist Reports Positive Top Line Results From Phase 2b Study of Icotrokinra Showing Potential to Transform the Treatment Paradigm for Patients With Ulcerative Colitis [Yahoo! Finance]
High
Report
Protagonist Reports Positive Top Line Results From Phase 2b Study of Icotrokinra Showing Potential to Transform the Treatment Paradigm for Patients With Ulcerative Colitis [Yahoo! Finance]
3/10
08:03 am
ptgx
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $54.00 price target on the stock.
High
Report
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $54.00 price target on the stock.
3/4
08:03 am
ptgx
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) had its price target raised by analysts at JPMorgan Chase & Co. from $53.00 to $57.00. They now have an "overweight" rating on the stock.
Low
Report
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) had its price target raised by analysts at JPMorgan Chase & Co. from $53.00 to $57.00. They now have an "overweight" rating on the stock.
3/3
01:47 pm
ptgx
News Flash: 10 Analysts Think Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Earnings Are Under Threat [Yahoo! Finance]
Low
Report
News Flash: 10 Analysts Think Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Earnings Are Under Threat [Yahoo! Finance]
3/3
12:41 pm
ptgx
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $54.00 price target on the stock.
Low
Report
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $54.00 price target on the stock.
3/3
12:17 pm
ptgx
Takeda-Protagonist Therapeutics Partnered Investigational Drug Hits Primary Goal In Late-Stage Study In Patients With Type Of Blood Cancer [Yahoo! Finance]
Low
Report
Takeda-Protagonist Therapeutics Partnered Investigational Drug Hits Primary Goal In Late-Stage Study In Patients With Type Of Blood Cancer [Yahoo! Finance]
3/3
07:01 am
ptgx
Protagonist and Takeda Announce Positive Topline Results from Phase 3 VERIFY Study of Rusfertide in Patients with Polycythemia Vera [Yahoo! Finance]
Medium
Report
Protagonist and Takeda Announce Positive Topline Results from Phase 3 VERIFY Study of Rusfertide in Patients with Polycythemia Vera [Yahoo! Finance]
2/26
06:48 pm
ptgx
The Polycythemia Vera Market Landscape Heats Up Amid Rising Competition Among Pharma Companies | DelveInsight [Yahoo! Finance]
Low
Report
The Polycythemia Vera Market Landscape Heats Up Amid Rising Competition Among Pharma Companies | DelveInsight [Yahoo! Finance]
2/24
11:32 am
ptgx
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $43.00 to $38.00. They now have a "neutral" rating on the stock.
Medium
Report
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $43.00 to $38.00. They now have a "neutral" rating on the stock.
2/24
08:16 am
ptgx
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) had its price target raised by analysts at HC Wainwright from $50.00 to $54.00. They now have a "buy" rating on the stock.
High
Report
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) had its price target raised by analysts at HC Wainwright from $50.00 to $54.00. They now have a "buy" rating on the stock.
2/21
10:04 pm
ptgx
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $58.00 price target on the stock.
Medium
Report
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $58.00 price target on the stock.
2/21
07:21 am
ptgx
Protagonist Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update [Yahoo! Finance]
Low
Report
Protagonist Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update [Yahoo! Finance]
2/20
01:07 pm
ptgx
BESREMi Achieves Strong Market Growth Amid Rising Demand for Polycythemia Vera Treatment [Yahoo! Finance]
Low
Report
BESREMi Achieves Strong Market Growth Amid Rising Demand for Polycythemia Vera Treatment [Yahoo! Finance]
2/7
12:49 pm
ptgx
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $58.00 price target on the stock.
Low
Report
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $58.00 price target on the stock.